Search results

Narrow your search

Result types

Showing 411 - 420 of 687 for "Bun %26 Associates" with applied filters

News & Analysis

Analysis of the First Applications of the Serious Accidents Punishment Act

21 June 2023 by Jipyong - South Korea

The Serious Accidents Punishment Act (“SAPA”) is a relatively new legislation that came into force on January 27, 2022.

News & Analysis

Trademark protection of signature poses and voices of celebrities in India: An uncharted territory

08 June 2023 by Rahul Chaudhry & Partners - India: Sakshi Mathur, Associate

Personality rights, commonly known as ‘right of publicity,’ guarantees an individual right in one’s personal attributes such as appearance, signature, voice, silhouette, face, features, gestures, expressions, mannerisms etc, paving way for an individual to use and commercialise one’s identity.

News & Analysis

Latest Update to “Guidelines for Workplace Risk Assessment“ to Impact Businesses in Korea

31 May 2023 by Lee & Ko - South Korea

On 22 May 2023, the Ministry of Employment and Labor (MOEL) announced a significant update to its “Guidelines for Workplace Risk Assessment“ (Guidelines), effective immediately.

News & Analysis

Revisiting 101 rule of Transfer Pricing in Indonesia

29 May 2023 by ABNR - Indonesia: Freddy Karyadi, Anastasia Irawati

As one of the designated Key Partners of the OECD, Indonesia has implemented some of the OECD’s Action Plans into its prevailing laws and regulations, including Action 8-10 concerning Transfer Pricing and Action 13 concerning Country-by-country Reporting.

News & Analysis

IP Issues and Implications Relating to ChatGPT

26 May 2023 by Lee & Ko - South Korea

ChatGPT is a conversational artificial intelligence (AI) service based on Generative Pre-trained Transformer (GPT), a language model grounded in artificial neural networks, developed by OpenAI.

News & Analysis

The SyCipLaw Corporate Bulletin - SEC MC No.6-2023 Bulletin

22 May 2023 by SyCip Salazar Hernandez & Gatmaitan

The Securities and Exchange Commission (SEC) has extended the deadline for applications for amnesty for late and non-filing of annual financial statements (AFS), general information sheets (GIS), as well as non-compliance with SEC Memorandum Circular No. 28, series of 2020 (Requirement for Corporations, Partnerships, Associations, and Individuals to Create and/or Designate E-mail Account Address and Cellphone Number for Transactions with the Commission) (MC28).

News & Analysis

Patenting Molecular Diagnostics

17 May 2023 by LexOrbis - DPS Parmar

The patent eligibility in every jurisdiction differs in content and form. It perhaps finds its justification in the stage of development the country is placed in relation to inventions of new technology or its adoption by the state technology groups.

News & Analysis

LexOrbis Successfully Hosts 5th edition of the AIPLA Women in IP Global Networking Event 2023

09 May 2023 by LexOrbis - India

On April 28, 2023, the India Habitat Centre in New Delhi was abuzz with over 100+ women professionals from different segments, all in attendance for the Women in IP Global Networking Event 2023 hosted by LexOrbis on behalf of the American Intellectual Property Law Association (AIPLA).

News & Analysis

DHC on irrational reasoning and requirements in patent refusal orders

04 May 2023 by Rahul Chaudhry & Partners - Madhuri Gupta, Senior Associate, Patents team

In a recent Judgement, the Delhi High Court (“Court”) decided on an appeal filed by Microsoft Corporation to set aside the decision of Controller General of Patents and Designs (“Controller”) dated 05th March 2012 refusing the grant of Indian patent application 487/DELNP/2006 (“subject patent”) under Section 15 of the Patents Act.

News & Analysis

Product Hopping and Ever-Greening of Patents in India

20 April 2023 by LexOrbis - Arun Kumar (Managing associate)

The Indian pharmaceutical market is one of the largest markets in the globe, both in terms of production and consumption. Several changes have been made to the patent and competition law due to the increasing challenges in the pharmaceutical market that directly impact the profit margin of pharmaceutical manufacturers. To increase these margins, pharmaceutical product manufacturing firms employ a variety of strategies. This article investigates the concept of “product hopping” and compares it with the practice of patent evergreening.